**NON-CONFIDENTIAL**

**APPLICATION FOR INVESTMENT**

Prior to submitting an investment opportunity to MABA, please first review our Investment Criteria document – to ensure that there is a fit.

**Application checklist. Please submit the following:**

* This Application (in PDF format, with the name of your company incorporated into the document name)
* Pitch deck
* An executive summary (which should not exceed three pages)
* Any relevant publications and data

***Please make sure that this application contains only non-confidential information.***

**MABA members include both individuals, as well as corporations. *Please do not provide any information you would not want seen by such entities.***

Please let us know if you have any questions or concerns about these requirement.

**By submitting an application, you acknowledge your acceptance of the terms noted above.**

If your company is selected by the Screening Committee to present, we will send you an invitation to present to the group. Companies will be scheduled to present on a first come, first serve basis.

We look forward to receiving your application.

|  |  |
| --- | --- |
| 1. Name of company (plus website – if any) |  |
| 1. Name of main contact (name, title, phone(s) & email) |  |
| 1. Location of company (if virtual, location of main contact) |  |
| **INTRODUCTION** |  |
| 1. What is the problem your company is trying to solve? |  |
| 1. Please describe your company’s solution to the problem, above, in plain English. |  |
| 1. Company start-up date |  |
| **FUNDING** |  |
| 1. Amount of money previously raised (total) |  |
| 1. Date last round closed |  |
| 1. Post-money valuation at the last round |  |
| 1. Amount of money being raised in current round |  |
| 1. Terms of current round (note/priced, discounts & caps), including pre-money valuation |  |
| 1. Date current round began & amount of money invested so far |  |
| 1. Investors already committed to participating in this round |  |
| 1. Including the current round, how much more investment capital will be required **to reach an exit** (including ***all*** ***future rounds*** and not including grants or other non-dilutive funding)? |  |
| 1. Minimum and Maximum amount of money available for MABA to invest in this round |  |
| 1. Where will your future funding (after this round) come from? Please include both dilutive and non-dilutive sources. |  |
| 1. What event will render further funding unnecessary (e.g., licensing deal, breakeven achieved, other) – and time to reach that event? |  |
| 1. Exit: What will an expected exit look like (type, timing, comps, ROI)? |  |
| 1. Describe non-dilutive or grant funding already received or applied for (please differentiate between received and applied for) |  |
| **PRODUCT** |  |
| 1. Is this a single product/service or a platform? |  |
| 1. If the company has developed a platform, what is the first product/service to be marketed commercially? |  |
| 1. Please provide a ***non-confidential*** description of how your product works |  |
| 1. Please provide data in support of the product’s efficacy |  |
| 1. Please indicate at least one significant publication that you believe supports your technology. (Be specific. If possible, please attach to submission) |  |
| 1. Are there toxicity or other issues associated with your product? |  |
| 1. Please list the reasons your product is superior to the standard of care, and to competitors’ products (including those pending approval) |  |
| 1. Current development stage (of first product/service) |  |
| 1. Briefly describe how product/device will be manufactured |  |
| **MARKET** |  |
| 1. Total addressable market (if platform – for first product only) |  |
| 1. Please identify all your known competitors |  |
| 1. In addition to patients, please identify all entities (doctors, hospitals, insurance companies, etc.) that would benefit from your product – financially and otherwise, please indicate how they would benefit, and their reasons to support the product’s adoption |  |
| 1. Sales and Go-to-Market Strategy |  |
| 1. If already selling – annual $ sales and number of customers |  |
| 1. Please identify current & anticipated alliance partners (please be specific) |  |
| **INTELLECTUAL PROPERTY (IP)** |  |
| 1. Describe the status and scope of patent protection, if any (number of applications, nature of claims, when filed/granted) |  |
| 1. Is there other IP – that might affect the product/service? |  |
| 1. Who owns the patents and other IP, if any? |  |
| 1. Describe the competitive IP landscape and how the company’s IP fits within that landscape |  |
| **REGULATORY & REIMBURSEMENT** |  |
| 1. FDA strategy, time to approval of primary indication/first product and approval pathway |  |
| 1. Reimbursement strategy (one sentence) |  |
| **TEAM** |  |
| 1. Management team (P&L/operating experience, significant accomplishments, prior fundraising experience and return to investors (If any)) |  |
| 1. Endorsement(s)/key supporters/key opinion leaders (specific names) |  |
| 1. Professional advisors (specific names) (legal, accounting, regulatory consultants, others?) |  |
| 1. Describe ***all*** special deals and circumstances with and between partners, related parties and anyone else (grant backs to founders, special licenses, etc.) |  |
| 1. Current salary and other compensation for each executive. How/will it change after financing? |  |
| 1. Is the team complete? What functions / capabilities are needed, and when will they be added? Have people already been identified for these positions? |  |
| 1. Are any of the team members related to one another (if so, how)? |  |
| **MISCELLANEOUS** |  |
| 1. How can investors lose their money? What are the biggest risks (competitive, regulatory, technical, etc.) standing between the company and successful commercialization and exit? |  |
| 1. Anticipated use of funds from this point forward |  |
| 1. How did you hear of MABA? |  |
| 1. If you have a short video (<5min) that you would like to share, please provide the link here. |  |
| 1. If you have applied to MABA in the past and were rejected, please list the reasons given for your rejection, and why these no longer apply. |  |

Please return this completed document – ***in PDF format and* *with your company name incorporated into the document name***, along with an executive summary, pitch deck, and other relevant documents, to: [info@bioangels.net](mailto:info@bioangels.net). Please make sure that your company name is in the subject line.

Thank you.

Mid Atlantic Bio Angels (MABA)